Pregabalin
Product Images NDC 50090-5177

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 50090-5177). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500905177)

This text contains information about the product "Pregabaltn" that comes in a packaging of 90 capsules and should be stored at 810 7 okGRgES ¢ temperature. The remaining text, including numbers and symbols, does not provide any relevant information.*

FDA Label Image

Figure 1 (Pregabalincaps Fig01)

FDA Label Image

Figure 2 (Pregabalincaps Fig02)

This text provides information about the percentage improvement in pain from baseline for patients taking Pregabalin 160mg for a 3-day period. The percentages listed are 100, 2, and 10. There are also some numbers listed in a table format, including 220, 23, 20, and 280, but it is unclear what they represent. The word "Facebo" is included, but it is not clear what it refers to.*

FDA Label Image

Figure 3 (Pregabalincaps Fig03)

This appears to be a chart or data with some numbers and drug names. It is not clear what the chart is referring to and what the numbers represent. Therefore, the description cannot be provided.*

FDA Label Image

Figure 4 (Pregabalincaps Fig04)

Not-Available. The text contains non-sensical characters and no readable sentence.*

FDA Label Image

Figure 5 (Pregabalincaps Fig05)

This appears to be a chart comparing the effectiveness of different doses of Fregabalin and Pregataiin (likely misspelled versions of the medications Pregabalin and Pregabalin). It also includes a placebo group. The chart measures the percentage of patients who experienced improvement in pain, as well as the percentage of improvement in pain from baseline. However, there is a lot of missing or unclear information, so the usefulness of this chart is limited.*

FDA Label Image

Figure 6 (Pregabalincaps Fig06)

FDA Label Image

Figure 7 (Pregabalincaps Fig07)

FDA Label Image

Figure 8 (Pregabalincaps Fig08)

The text describes a chart showing the percentage of patients who experienced improvement in pain from baseline after taking either a daily dose of Pregabalin 300mg or Pregabalin 450mg. The chart also includes a comparison with a placebo group. The X-axis shows the range of percent improvement from 20 to 280.*

FDA Label Image

Figure 9 (Pregabalincaps Fig09)

This appears to be a chart showing the estimated percentages of subjects without LTR (not clear what this stands for) over a period of 120 days. The chart also includes labels for "Progabain" and "Placebo."*

FDA Label Image

Figure 11 (Pregabalincaps Fig10)

FDA Label Image

Figure 12 (Pregabalincaps Fig11)

This table shows the percentage of subjects who improved from baseline to week 16 for pregabalin and placebo. The values range from 100 to 280 and are plotted against specific values of 210 to 270.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalincaps Formula)

This is a medical formula to calculate the creatinine clearance rate (CLCT) in patients, which helps to determine the kidney function. The formula requires the patient's age, weight, and serum creatinine levels in milligrams per deciliter (mg/dL). For female patients, the result is multiplied by 0.85.*

FDA Label Image

Chemical Structure (Pregabalincaps Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.